Interactive Decision Support Tool: Expert Treatment Guidance for Patients With Advanced Soft Tissue Sarcoma
  • CME

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with advanced soft tissue sarcoma with those of 5 renowned experts.
William Tap, MD
Program Director
Vicki L. Keedy, MD
Shreyaskumar R. Patel, MD
Richard F. Riedel, MD
Brian A. Van Tine, MD, PhD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: April 10, 2019 Expiration: April 9, 2020
Interactive Decision Support Tool
Expert Guidance for Advanced STS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss contemporary multidisciplinary strategies used in the management of advanced STS to formulate treatment plans for patients
  • Plan individualized treatment strategies based on disease characteristics as well as patient age/fitness, comorbidities, and preferences
  • Apply the available data, treatment guidelines, and expert recommendations to select therapy for advanced STS
  • Evaluate key safety and efficacy data on recently approved therapies for advanced STS in the context of evolving treatment paradigms and multimodality sequencing in multiple lines of care

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

William Tap, MD

Chief, Sarcoma Medical Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

William Tap, MD, has disclosed that he has received consulting fees from Adaptimmune, Agios, Blueprint, Daiichi Sankyo, Eisai, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, Lilly, Loxo, Nanocell, Novartis, and Plexxikon and has served on scientific advisory boards for and has ownership interest in Atropos and Certis Oncology Solutions.


Vicki L. Keedy, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Vicki L. Keedy, MD, has disclosed that she has received consulting fees from Karyopharm and funds for research support from Advenchen, BioMed Valley Discoveries, Daiichi Sankyo, GlaxoSmithKline, Immune Design, Lilly, MedPacto, Plexxikon, Roche, and Tracon.
Shreyaskumar R. Patel, MD

Robert R. Herring Distinguished Professor of Medicine
Medical Director, Sarcoma Center
University of Texas MD Anderson Cancer Center
Houston, Texas

Shreyaskumar R. Patel, MD, has disclosed that he has received consulting fees from Epizyme, Immune Design, Janssen, Lilly, and Novartis and funds for research support from Blueprint, Eisai, and Janssen.
Richard F. Riedel, MD

Associate Director for Clinical and Translational Research
Duke Sarcoma Program
Duke Cancer Institute
Associate Professor with Tenure
Division of Medical Oncology
Duke University Medical Center
Durham, North Carolina

Richard F. Riedel, MD, has disclosed that he has received consulting fees from Bayer, Eisai, EMD Serono, Janssen, Lilly, and Loxo and funds for research support from AADi, Arog, Karyopharm, Ignyta, Immune Design, Lilly, NanoCarrier, Novartis, Oncternal, Plexxicon, Threshold, and Tracon and that his spouse receives a salary from Limbguard.
Brian A. Van Tine, MD, PhD

Associate Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Brian A. Van Tine, MD, PhD, has disclosed that he has received consulting fees from CytRx, Janssen, and Lilly; fees for non-CME/CE services from Caris, Janssen, and Lilly; and funds for research support from Merck and Pfizer.


Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other oncology healthcare providers who care for patients with STS.


The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with soft tissue sarcoma (subtypes with nonspecific histologies) and establish more efficient infrastructures to support physician collaboration and timely, more prevalent referrals among community oncologists and expert sarcoma treatment centers.


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 10, 2019, through April 09, 2020:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.


Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Treatment Guidance for Patients With Advanced Soft Tissue Sarcoma,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making treatment decisions on optimal regimens to use for patients with advanced soft tissue sarcoma, based on specific patient characteristics. The information provided is based on the guidance of sarcoma experts Vicki L. Keedy, MD; Shreyaskumar R. Patel, MD; Richard F. Riedel, MD; William Tap, MD; and Brian A. Van Tine, MD, PhD, MD, who provided their treatment recommendations based on the specific patient criteria and characteristics indicated in this tool.

Please note: These data were compiled in February 2019 and include the opinions of the experts at that time.

Although the information contained in the “Interactive Decision Support Tool: Expert Treatment Guidance for Patients With Advanced Soft Tissue Sarcoma” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Related Content

Downloadable resource guide for patients who are receiving an FDA-approved BTK inhibitor, acalabrutinib or ibrutinib, from CCO.

Released: June 20, 2019

Downloadable slides on treatment strategies for CLL including the most recent data on BTK inhibitors, BCL-2 inhibitor, PI3K inhibitors, and CAR T-cell therapy.

John M. Burke, MD Nicole Lamanna, MD Released: June 19, 2019

Enter characteristics of your patient with acute myeloid leukemia (AML) into this online tool to receive treatment recommendations from 5 experts

Jeffrey E. Lancet, MD Farhad Ravandi, MD B Douglas Smith B. Douglas Smith, MD Roland B. Walter, MD, PhD, MS Eunice S. Wang, MD Released: June 12, 2019

Phase III TAGS: Subgroup analyses and QoL with trifluridine/tipiracil in previously treated metastatic gastric/GEJ cancer as reported by CCO from ASCO 2019

Released: June 11, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?